Evaluation of cd53 marker expression in triple negative breast carcinoma: a hospital based cross sectional study

Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/2157

Full metadata record

DC Field	Value	Language
dc.contributor.author	REG NO:BN0122003	-
dc.date.accessioned	2026-03-12T06:23:47Z	-
dc.date.available	2026-03-12T06:23:47Z	-
dc.date.issued	2025	-
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/2157	-
dc.description.abstract	ABSTRACT Background Triple-negative breast cancer (TNBC) is a molecular subtype that develops independently of estrogen, progesterone, and HER2 amplification. Recent research highlights the role of immune surveillance in carcinogenesis, suggesting that CD53 could serve as a potential prognostic marker for TNBC. This study aims to examine CD53 expression in TNBC. Objectives This study aims to study expression of CD53 as IHC marker and correlate its expression with clinicopathological parameters in TNBC.	en_US
dc.language.iso	en_US	en_US
dc.publisher	KLE Academy of Higher Education and Research, Belagavi	en_US
dc.subject	TNBC, Breast cancer, CD53, TILs, Molecular, Tumor microenvironment, Prognostic	en_US
dc.title	Evaluation of cd53 marker expression in triple negative breast carcinoma: a hospital based cross sectional study	en_US
dc.type	Dissertations	en_US
Appears in Collections:	Pathology

Files in This Item:

File	Description	Size	Format
BN0122003.pdf		6.62 MB	Adobe PDF	View/Open